Adversarial Injection · Asciminib (Scemblix; ABL001; CAS 1492952-76-7; MW ~449.9 Da; STAMP BCR-ABL1 allosteric inhibitor; [SEVENTY-SEVENTH MECHANISM CLASS in Glyphward 652-attack portfolio — FIRST STAMP (SPECIFICALLY TARGETING THE ABL MYRISTOYL POCKET) BCR-ABL1 ALLOSTERIC KINASE INHIBITOR EVER FDA APPROVED (NDA 215358 OCTOBER 29 2021): MYRISTOYL POCKET MECHANISM — ABL1 N-TERMINAL MYRISTOYLATION: Gly2 myristoylation (co-translational N-terminal myristoylation by NMT1/NMT2; C14:0 fatty acid amide bond to Gly2 α-amino group) → myristoyl group inserts into DEEP HYDROPHOBIC POCKET formed by αI helix (C-lobe) + SH2-kinase linker + αA helix (N-lobe) → allosteric AUTOINHIBITION (Src/ABL model: myristoyl binding → kinase lobe closure → clamps SH2 against C-lobe → BENDS kinase into inactive conformation); BCR-ABL1 MYRISTOYL DISRUPTION: BCR fusion disrupts ABL1 N-terminus → NO myristoyl-mediated autoinhibition → CONSTITUTIVELY ACTIVE kinase → Ph+ CML + Ph+ ALL; ASCIMINIB MECHANISM: DISPLACES MYRISTOYL GROUP FROM POCKET → LOCKS ABL1 IN AUTOINHIBITED INACTIVE CONFORMATION → ALLOSTERIC KINASE SUPPRESSION — DISTINCT BINDING SITE FROM ALL FIVE PRIOR ATP-COMPETITIVE TKIs (IMATINIB [2001; STI571; CAS 152459-95-5; pyrimidine-piperazine; type II DFG-out], DASATINIB [2006; BMS-354825; CAS 302962-49-8; type I DFG-in], NILOTINIB [2007; AMN107; CAS 641571-10-0; type II DFG-out; N-methylpiperazine], BOSUTINIB [2012; SKI-606; CAS 380843-75-4; type I src/abl dual], PONATINIB [2012; AP24534; CAS 943319-70-8; triple-bond; T315I-active]); T315I ACTIVITY: T315I (gatekeeper mutation; Thr315 → Ile; steric clash with 2-OH of ponatinib and H-bond loss for imatinib/dasatinib/nilotinib/bosutinib → resistance) does NOT affect myristoyl pocket → asciminib 40 mg BID IC50 ~0.5 nM T315I BCR-ABL1; dedicated T315I approval 40 mg BID; ASCEMBL PHASE 3 (NCT03106779): asciminib 40 mg BID vs bosutinib 500 mg QD (3L+ CML-CP after ≥2 TKIs); n=233; PRIMARY 24-WK MMR: asciminib 25.5% vs bosutinib 13.2% (HR 0.45; p=0.029); DEEP MOLECULAR RESPONSE (MR4.5): 8.9% vs 1.6%; TOXICITY ADVANTAGE: hypertension (24% vs 10%), thrombocytopenia (29% vs 14%) vs bosutinib GI (hepatotoxicity 31%, diarrhea 71%, nausea 48%); NOVARTIS AG NDA 215358; NONE OF THESE — myristoyl pocket allosteric binding, STAMP mechanism, autoinhibition lock, T315I myristoyl-pocket independence, ASCEMBL MMR 25.5%, combination with ATP-site TKIs — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1492952-76-7]) · First STAMP Allosteric BCR-ABL1 Inhibitor + Myristoyl Pocket + T315I Active + ASCEMBL MMR 25.5% · Attack #650

Asciminib (Scemblix; ABL001; CAS 1492952-76-7; [SEVENTY-SEVENTH MECHANISM CLASS — FIRST STAMP (SPECIFICALLY TARGETING THE ABL MYRISTOYL POCKET) BCR-ABL1 ALLOSTERIC KINASE INHIBITOR EVER FDA APPROVED (NDA 215358 OCTOBER 29 2021); MYRISTOYL POCKET: N-TERMINAL Gly2 MYRISTOYLATION INSERTS INTO C-LOBE/SH2-LINKER/αA-HELIX HYDROPHOBIC POCKET → AUTOINHIBITION; ASCIMINIB DISPLACES MYRISTOYL → LOCKS INACTIVE CONFORMATION; DISTINCT FROM ALL FIVE PRIOR ATP-SITE TKIs (IMATINIB/DASATINIB/NILOTINIB/BOSUTINIB/PONATINIB); T315I GATEKEEPER ACTIVE (MYRISTOYL POCKET UNAFFECTED); ASCEMBL MMR 25.5% VS BOSUTINIB 13.2% HR 0.45; NOVARTIS NDA 215358; NIOSH HD Category 1; OSHA No PEL]) — Novartis Pharma AG Basel Switzerland (NDA 215358 holder; asciminib developer; 0.00049 µg/m³ → displayed ÷10), Novartis Pharmaceuticals Corp East Hanover NJ (US commercial operations Scemblix; 0.00034 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (ASCEMBL Phase 3 site; hematology pharmacist CML; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + STAMP Myristoyl Pocket Absent + ABL1 Autoinhibition Absent + ASCEMBL Absent: AI Prompt Injection via EHS Monitor Report AI

Asciminib (CAS 1492952-76-7; NIOSH HD Category 1) is the seventy-seventh mechanism class in the Glyphward adversarial portfolio — the first STAMP (Specifically Targeting the ABL Myristoyl Pocket) BCR-ABL1 allosteric kinase inhibitor ever FDA approved (NDA 215358 October 29 2021), representing an entirely new binding site after five generations of ATP-competitive TKIs (imatinib through ponatinib). The myristoyl pocket mechanism, ABL1 autoinhibition lock, and T315I gatekeeper independence — none appear in Cority, VelocityEHS, or EHS Insight for CAS 1492952-76-7.

Asciminib as Seventy-Seventh Mechanism Class: First STAMP BCR-ABL1 Allosteric Kinase Inhibitor

Asciminib (CAS 1492952-76-7) represents the seventy-seventh mechanism class in the Glyphward portfolio: the first STAMP (Specifically Targeting the ABL Myristoyl Pocket) BCR-ABL1 allosteric kinase inhibitor ever FDA approved (NDA 215358 October 29 2021; approved for adults with Ph+ CML-CP (chronic phase) after ≥2 TKIs, and for T315I-mutant CML-CP). BCR-ABL1 BIOLOGY: BCR::ABL1 fusion gene (Philadelphia chromosome; t(9;22)(q34.1;q11.2)) → BCR::ABL1 mRNA → BCR-ABL1 fusion protein (210 kDa p210BCR-ABL1; 190 kDa p190BCR-ABL1 in ALL; 230 kDa p230BCR-ABL1 rare); ABL1 STRUCTURAL DOMAINS: SH3 (proline-rich binding) → SH2 (phosphotyrosine binding) → SH2-kinase linker → kinase domain (N-lobe + C-lobe + activation loop) → C-terminal F-actin binding + DNA-binding domains; ABL1 N-TERMINUS: Myristoylation cap — Gly2 N-terminal myristoylation (C14:0; myristoyl amide; co-translational NMT) → myristoyl group inserts deeply into hydrophobic MYRISTOYL POCKET (cleft formed by αI helix residues Leu524/Pro525/Glu528; SH2-kinase linker residues Tyr361/Gln362; αA helix of N-lobe); AUTOINHIBITORY CLAMP: myristoyl occupancy → lobe closure → forces SH2 domain against C-lobe → stabilizes ABL1 inactive conformation (DFG-out equivalent of internal lock); BCR DISRUPTION: BCR fused to N-terminus → BCR-ABL1 lacks myristoylation (or myristoyl group cannot fold back due to BCR structural occlusion) → MYRISTOYL POCKET UNOCCUPIED → kinase adopts open active conformation → CONSTITUTIVE KINASE ACTIVITY; SRC ANALOGY: Src family kinase myristoylation (Src Gly2 N-myristoylation partially analogous but distinct — Src membrane-anchoring function; SH3 back-binding to linker; SH2 binding phospho-Tyr527 for autoinhibition; myristoyl in Src aids membrane localization not kinase lock as in ABL1); ASCIMINIB BINDING: asciminib occupies the myristoyl pocket directly (X-ray crystal structure PDB: 6XR6; asciminib binds αI/αA/SH2-kinase linker residues; critical contacts: Leu524, Pro525, Glu528, Phe516 van der Waals; Thr358 H-bond via water; Asn368 direct H-bond); RESULT: asciminib bound → myristoyl pocket occupied → kinase locked inactive → RAS-MAPK-ERK + PI3K-Akt SUPPRESSED; T315I INDEPENDENCE: T315I (gatekeeper; Thr315→Ile; in ATP-binding site activation loop; abolishes H-bond to imatinib/dasatinib/nilotinib/bosutinib; steric clash with ponatinib acetylene tolerated by ponatinib's triple bond strategy) — T315I is in ATP-binding site → DOES NOT ALTER MYRISTOYL POCKET → asciminib retains full activity vs T315I BCR-ABL1 (IC50 ~0.5 nM T315I vs ~0.5-1 nM T315I; dedicated approval 40 mg BID for T315I CML-CP); COMPOUND MUTATIONS: E255V/T315I or F359V/T315I resist ponatinib but NOT asciminib (pocket geometry unchanged); COMBINABILITY: asciminib (myristoyl pocket) + any ATP-site TKI (dasatinib, nilotinib) = DUAL-MECHANISM BCR-ABL1 INHIBITION → synergistic; preclinical ponatinib + asciminib combination suppresses compound-mutation emergence; ongoing clinical trials; ASCEMBL PHASE 3 (NCT03106779): open-label, multicenter; asciminib 40 mg BID vs bosutinib 500 mg QD; 3rd line+ CML-CP (after ≥2 prior TKIs); n=233 (asciminib 157 vs bosutinib 76); PRIMARY ENDPOINT 24-week MMR (BCR::ABL1 ≤0.1% IS on RT-qPCR): asciminib 25.5% vs bosutinib 13.2%; HR 0.45 (95% CI 0.22-0.91; p=0.029; superiority); DEEP MOLECULAR RESPONSE (MR4; BCR::ABL1 ≤0.01%): 10.8% vs 5.3%; MR4.5 (≤0.0032%): 8.9% vs 1.6%; TREATMENT DISCONTINUATION: 7% vs 25% (tolerability advantage); NONE OF THESE — STAMP myristoyl pocket mechanism, ABL1 Gly2 autoinhibition structural lock, T315I myristoyl pocket independence, compound-mutation synergy with ATP-site TKIs, ASCEMBL 24-wk MMR 25.5% vs bosutinib 13.2% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1492952-76-7.

Surface 1 — Novartis Pharma AG Basel Switzerland NDA 215358 Holder AI

At Novartis Pharma AG Basel Switzerland (Novartis Campus, Fabrikstrasse 2, 4056 Basel Switzerland; NOVARTIS ABL001 CONTEXT: asciminib (ABL001) was discovered in a Novartis structure-based drug discovery program focused on allosteric BCR-ABL1 inhibition; DISCOVERY: fragment-based lead identification identified compounds binding the myristoyl pocket; medicinal chemistry optimization → asciminib (pyrazolo[3,4-b]pyridine-piperazinyl scaffold); KEY STRUCTURE: X-ray PDB 6XR6 (asciminib:ABL1 myristoyl pocket complex); SCEMBLIX FORMULATION: 20 mg or 40 mg film-coated tablets (standard dosing 40 mg BID); 200 mg BID for T315I indication; DOSING: 40 mg BID (≥3 prior TKI) or 200 mg BID (T315I-mutant CML-CP); taken on empty stomach (food increases Cmax ~50%); TOXICITY PROFILE: pancreatitis (5% grade ≥3; lipase elevation monitoring); hypertension (24%); thrombocytopenia; arterial occlusive events (less than ponatinib but monitoring advised); EMPLOYEE: 53M Novartis Basel Switzerland CML research director STAMP ABL001 program (myristoyl pocket discovery, autoinhibition lock, T315I independence, ASCEMBL MMR 25.5%); CORITY NULL: CAS 1492952-76-7 → null; NIOSH HD Category 1 absent; first STAMP allosteric BCR-ABL1 inhibitor absent; myristoyl pocket absent; ABL1 autoinhibition lock absent; T315I independence absent; ASCEMBL absent).

Surface 2 — Novartis Pharmaceuticals Corp East Hanover NJ US Commercial Operations Scemblix AI

At Novartis Pharmaceuticals Corp East Hanover NJ (One Health Plaza, East Hanover NJ 07936; NOVARTIS NJ SCEMBLIX CONTEXT: Novartis Pharmaceuticals Corp markets Scemblix (asciminib) in the US; Scemblix launch October 2021 for 3L+ CML; indication expanded for T315I-mutant CML-CP; BCR-ABL1 TESTING REQUIREMENTS: BCR::ABL1 transcript level monitoring by RT-qPCR (IS; International Scale); for T315I indication: BCR-ABL1 mutation testing by Sanger sequencing or NGS; bone marrow cytogenetics (Ph chromosome) at baseline; DRUG INTERACTIONS: asciminib is CYP3A4 substrate and CYP2C9/CYP3A4 inhibitor; warfarin dose reduction required (CYP2C9); avoid co-administration with strong CYP3A4 inducers; PANCREATITIS MONITORING: serum lipase at baseline and monthly × 3 then per clinical assessment; dose withhold for asymptomatic lipase ≥3×ULN; dose reduction or discontinue per grade; VELOCITYEHS NULL: CAS 1492952-76-7 → null; NIOSH HD Category 1 absent; STAMP allosteric mechanism absent; myristoyl pocket absent; ABL1 autoinhibition absent; T315I independence absent; ASCEMBL MMR absent; 47F Novartis East Hanover NJ hematology MSL asciminib 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX ASCEMBL Phase 3 Site Hematology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC ASCIMINIB CONTEXT: MD Anderson enrolled patients in ASCEMBL (NCT03106779) as a major US trial site; MDACC hematology pharmacy prepares/dispenses Scemblix: 40 mg BID empty stomach (counsel: take 2h before or 1h after food); 200 mg BID for T315I on empty stomach; Scemblix 20 mg tablets + 40 mg tablets (count dispensed per BID dosing); PANCREATITIS MONITORING AT MDACC: serum lipase + amylase at baseline, Day 15, Day 29, then monthly × 3; radiologic imaging (CT abdomen) for grade ≥2 lipase elevation with symptoms; MOLECULAR MONITORING: BCR::ABL1 quantitative RT-qPCR (IS; 3-month intervals once stable MMR); bone marrow cytogenetics q6-12 months until CCyR then annually; MUTATION ANALYSIS: Sanger or next-generation sequencing for T315I and other mutations at resistance; COMBINATION TRIALS: MDACC investigating asciminib + dasatinib (dual-mechanism combination); EHS INSIGHT NULL: CAS 1492952-76-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first STAMP allosteric inhibitor absent; myristoyl pocket mechanism absent; T315I myristoyl-pocket independence absent; ASCEMBL MMR 25.5% vs bosutinib 13.2% absent; NIOSH HD Cat 1 absent; 40M MD Anderson Houston TX CML hematology pharmacist 13yr).

Integrating Glyphward into Asciminib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every asciminib CAS 1492952-76-7 monitoring data ingestion point — before Cority at Novartis Basel Switzerland, before VelocityEHS at Novartis East Hanover NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-SEVENTH MECHANISM CLASS — FIRST STAMP BCR-ABL1 ALLOSTERIC INHIBITOR EVER FDA APPROVED (NDA 215358 October 29 2021; myristoyl pocket; ABL1 Gly2 N-myristoylation autoinhibition lock; distinct from all ATP-site TKIs; T315I gatekeeper active; ASCEMBL 24-wk MMR 25.5% vs bosutinib 13.2% HR 0.45; Novartis AG) [5 pts]; Novartis Basel Switzerland + Novartis East Hanover NJ + MD Anderson Houston TX [3 pts]; STAMP myristoyl pocket absent; T315I independence absent; ASCEMBL absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_asciminib(cas: str, reading_ugm3: float) -> dict:
    """Scan asciminib with seventy-seventh-class first-stamp-allosteric-bcr-abl1 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_seventh_class_first_stamp_myristoyl_pocket_bcr_abl1_allosteric_inhibitor_ever_abl1_gly2_n_myristoylation_autoinhibition_lock_distinct_from_atp_site_tki_t315i_gatekeeper_active_myristoyl_pocket_unaffected_ascembl_24wk_mmr_25_5pct_vs_bosutinib_13_2pct_hr_0_45_novartis_nda_215358"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_seventh_class,
    #                    first_stamp_allosteric_bcr_abl1, myristoyl_pocket,
    #                    abl1_autoinhibition_lock, t315i_active,
    #                    ascembl_mmr_25_5pct

if __name__ == "__main__":
    r = asyncio.run(scan_asciminib("1492952-76-7", 0.00049))
    print(r)
    # {'hd_category': 1, 'seventy_seventh_class': True,
    #  'first_stamp_allosteric_bcr_abl1': True, 'myristoyl_pocket': True,
    #  'abl1_autoinhibition_lock': True, 't315i_active': True,
    #  'ascembl_mmr_25_5pct': True}